Biosimilars market is projected to surge to $143.6 billion by 2031, expanding at a robust CAGR of 24.7%

The biosimilars market stands at a remarkable inflection point, poised to redefine the economics of global healthcare. Valued at $15.9 billion in 2021, the global biosimilars market is projected to surge to $143.6 billion by 2031, expanding at a robust CAGR of 24.7% over the forecast period from 2022 to 2031, according to Allied Market Research. This extraordinary trajectory reflects a convergence of powerful forces: an accelerating patent cliff among blockbuster biologics, relentless pressure on healthcare systems to contain costs, rising incidence of chronic diseases, and the steady maturation of regulatory pathways across key geographies.

Once viewed as niche alternatives, biosimilars have now emerged as strategic imperatives for payers, providers, and patients worldwide. From oncology wards in North America to rural clinics in Southeast Asia, these highly similar versions of approved biological therapies are transforming access to life-changing treatments. The biosimilars market represents not just a financial opportunity of significant scale, but a fundamental shift in how the world approaches biologic medicine.

Download Sample PDF at: https://www.alliedmarketresearch.com/request-sample/162

What Are Biosimilars? Market Definition

Biosimilars are biotherapeutic products that are highly similar in quality, safety, and efficacy to an already approved reference biological medicine, often referred to as the originator biologic or reference product. Unlike small-molecule generic drugs, which can be chemically synthesized as exact replicas, biologics are large, complex proteins derived from living cells. This inherent complexity means that biosimilars cannot be identical to their reference products, but they must demonstrate no clinically meaningful differences in terms of safety, purity, and potency.

The biosimilars industry encompasses a broad range of biological molecules, including monoclonal antibodies (mAbs), erythropoietins, insulins, granulocyte-colony stimulating factors (G-CSFs), human growth hormones, and interferons. These products are developed using recombinant DNA technology and undergo rigorous analytical, preclinical, and clinical testing to confirm biosimilarity before receiving regulatory approval. The development process, while less costly than that of an original biologic, still requires substantial investment in characterization, manufacturing process development, and clinical evidence generation.

Segmentation Analysis

By Type

The biosimilars market is classified by type into erythropoietin, human growth hormone, monoclonal antibodies, granulocyte-colony stimulating factor (G-CSF), insulin, and others. Among these, the monoclonal antibodies segment demonstrated the strongest revenue performance in 2021, accounting for more than one-fourth of total market revenue. The therapeutic versatility of mAbs, which are deployed across cancer treatment, rheumatoid arthritis, multiple sclerosis, Crohn's disease, and psoriasis, underpins their commercial dominance. Their high reference product prices also mean that biosimilar versions offer the most dramatic cost savings, driving both payer mandates and patient access programs.

Beyond mAbs, the insulin biosimilars sub-segment is drawing significant attention in light of the global diabetes epidemic. Biocon Biologics, for example, has received FDA approval for biosimilar insulin formulations, providing patients with more affordable options in a category where reference product pricing has faced intense scrutiny. The erythropoietin segment continues to serve the large and growing population of patients with anemia associated with chronic kidney disease and chemotherapy, while G-CSF biosimilars such as Novartis's Ziextenzo help reduce infection risk in chemotherapy patients at meaningfully lower cost.

By Application

From an application perspective, the biosimilars market spans oncology diseases, chronic and autoimmune diseases, blood disorders, and others. The oncology diseases segment held the lion's share in 2021, representing over two-fifths of total revenue, and is forecast to maintain this leadership position while posting the highest CAGR of 26.0% through 2031. The relentless rise in global cancer incidence, combined with the prohibitive cost of originator oncology biologics, has made biosimilar substitution an economic necessity for health systems in virtually every region.

The chronic and autoimmune diseases segment is the second largest application area, with biosimilars targeting conditions such as rheumatoid arthritis, psoriasis,

ankylosing spondylitis, and inflammatory bowel disease. The broad patient populations and lifetime treatment durations associated with these indications make them commercially compelling for biosimilar manufacturers. Blood disorders, including anemia and neutropenia, round out the key application areas, supported by well-established biosimilar products in the erythropoietin and G-CSF categories.

Ask to Our Industry Expert: https://www.alliedmarketresearch.com/request-for-customization/162

Regional Analysis

The global biosimilars market exhibits distinct regional dynamics, with each geography contributing a unique blend of regulatory environment, healthcare infrastructure, and disease burden to the overall growth narrative.

North America

North America held the largest revenue share of the biosimilars market in 2021, a position supported by a robust healthcare infrastructure, well-established regulatory pathways, and an accelerating wave of FDA biosimilar approvals. The United States, as the world's largest pharmaceutical market, has seen transformative biosimilar activity since the first FDA approval in 2015. By 2023, over 40 biosimilars had received FDA clearance, with more than 30 commercial launches completed. The enactment of the Advancing Education on Biosimilars Act of 2021 and favorable reimbursement provisions under the Biosimilar User Fee Act have further entrenched North America as the most commercially dynamic biosimilar geography. Physician acceptance and patient access programs sponsored by leading manufacturers continue to advance biosimilar penetration across oncology, immunology, and endocrinology.

Europe

Europe occupies a uniquely important position in the biosimilars market, having pioneered the regulatory framework for biosimilar approval through the European Medicines Agency (EMA) in 2006. Today, European nations benefit from two decades of biosimilar experience and some of the highest substitution rates in the world. Germany leads European biosimilar uptake, supported by a mandatory tender system that incentivizes pharmacies and hospitals to dispense biosimilar versions. France has

implemented reimbursement policies that actively favor biosimilar prescription, while the United Kingdom leverages NHS procurement frameworks to achieve significant cost containment through biosimilar substitution. In January 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued favorable opinions recommending marketing authorizations for three additional biosimilar products, underscoring the region's continued regulatory momentum. The high prevalence of rheumatoid arthritis, multiple sclerosis, and oncological conditions across European nations sustains strong long-term demand across the full spectrum of biosimilar therapeutic classes.

Asia-Pacific

Asia-Pacific represents the most dynamic growth frontier of the biosimilars market, expected to post the highest regional CAGR over the 2022 to 2031 forecast period. The region's extraordinary growth potential is rooted in its vast and aging population, rapidly expanding healthcare infrastructure, and the mounting burden of chronic diseases in economies that have historically underserved biologic-class therapies due to cost constraints. China has emerged as a global manufacturing powerhouse, with domestic biosimilar developers such as 3SBio and Qilu Pharmaceutical scaling up production capabilities while simultaneously seeking international regulatory approvals. Japan is witnessing accelerating biosimilar adoption, driven by strong government support for cost-efficient pharmaceuticals and a healthcare system under pressure from an unusually aged population.

Key players in the industry-

Exxon Mobil Corporation
Haihang Industry Co., Ltd.
Kent elastomer products
Kuraray Co.
Shell,Ltd.
SIBUR
Dupont
The Goodyear Tire & Rubber Company

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com/reports-store/life-sciences

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.